Amicus Therapeutics Inc. Stock
Price
Target price
€8.75
€8.75
-1.690%
-
-1.690%
€17.78
16.05.24 / Tradegate
WKN: A0MSMZ / Symbol: FOLD / Name: Amicus / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Amicus Therapeutics Inc. Stock
We can see a decrease in the price for Amicus Therapeutics Inc.. Compared to yesterday it has lost €0.000 (-1.690%).
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Amicus Therapeutics Inc..
As a result the target price of 17 € shows a very positive potential of 94.29% compared to the current price of 8.75 € for Amicus Therapeutics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Amicus Therapeutics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Amicus Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Amicus Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc. | -1.690% | 1.744% | -11.616% | -11.616% | -34.211% | 18.243% | - |
| Opko Health Inc. | -0.610% | 2.128% | 4.170% | -23.931% | -15.144% | -58.982% | -34.849% |
| Catalent Inc. | -0.200% | -1.910% | -2.363% | 47.977% | 23.374% | -38.388% | 25.043% |
| Repligen Corp. | -0.730% | 4.669% | 7.153% | 7.225% | -5.698% | 9.075% | - |
Comments
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at UBS Group AG from $20.00 to $19.00. They now have a "buy" rating on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at Morgan Stanley from $20.00 to $19.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at Bank of America Co. from $14.00 to $13.00. They now have a "buy" rating on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
